Chinese Medical University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT01550055
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chinese Medical University First Affiliated Hospital | The First Hospital of Chinese Medical University

Active Ingredients

Drugs in Phase 3 Trials (2)

cetuximab (erbitux) (1 trial)

irinotecan (Camptosar) (1 trial)

Drugs in Phase 2 Trials (3)

orelabrutinib (1 trial)

sintilimab (1 trial)

tislelizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5